Molecular risk testing: A smarter system for thyroid cancer care

Molecular risk testing: A smarter system for thyroid cancer care Oliver Bathe, Professor of Surgery and Oncology and CEO of Qualisure Diagnostics, calls for policymakers to support molecular risk testing to improve patient care and reduce healthcare costs associated with thyroid cancer treatment. Papillary thyroid cancer (PTC) is one of the most commonly diagnosed endocrine cancers worldwide. Though survival rates are high, many patients undergo more treatment than necessary. The current system often relies on imprecise tools to assess risk, leading to aggressive care even when the cancer poses minimal threat. This mismatch creates unnecessary complications, higher costs, and avoidable burdens for patients and healthcare systems alike.